

XX
AC AAU07141;
XX
DE 24-OCT-2001 (first entry)
XX Human CRIM1 protein.
XX
CRIM-1; Human; human chromosome 2p21-16 3'; ophthalmological; neuroprotective; gene therapy; neurodegenerative disease; eye disorder; neurodegenerative diseases; renal and kidney disease; bone and tooth abnormalities; wounds and skin damage, e.g. by use of the nucleic acid in gene therapy by using antibodies directed against CRIM1 polypeptides. The present sequence represents human CRIM1 (aka S52).
XX
OS Homo sapiens.
XX
PH Key Location/Qualifiers
FT Peptide 1..17
FT /label= Signal-peptide
FT Domain 1..901
FT /label= Extracellular-domain
FT /note= "This sequence is specifically claimed in claim 15."
FT Protein 18..1036
FT /label= CRIM1
FT Region 200..207 "Conserved N-terminal motif"
FT Region 336..391
FT /label= CR_1
FT /note= "Cysteine rich repeat"
FT Region 403..456
FT /label= CR_2
FT /note= "Cysteine rich repeat"
FT Misc-difference 414
FT /note= "Encoded by GAC"
FT Region 608..662
FT /label= CR_3
FT /note= "Cysteine rich repeat"
FT Region 679..734
FT /label= CR_4
FT /note= "Cysteine rich repeat"
FT Region 753..808
FT /label= CR_5
FT /note= "Cysteine rich repeat"
FT Region 819..873
FT /label= CR_6
FT /note= "Cysteine rich repeat"
FT Region 900..951
FT /label= CR_7
FT Region 952..1036
FT /note= "Cysteine rich repeat"
XX WO200138519-A1.
PR 31-MAY-2001.
XX
24-NOV-2000; 2000WO-AU01435.
XX
26-NOV-1999; 99AU-0004348.
XX
(UQ) UNIV QUEENSLAND.
XX Little M, Yamada T, Holmes G, Georgas K, Kolle G, Wilkinson L;
XX WPI; 2001-34395/-36.
N-PSDB; AAS11601.
XX
PT Nucleic acids from human chromosome 2p21-16 3' and the encoded peptide, useful for preventing, diagnosing and treating e.g. eye disease, especially cataract formation.
PS Claim 11; Fig 1; 16pp; English.
XX
CC The invention relates to nucleic acids from human chromosome 2p21-16 3' and the encoded peptide (and mouse and chicken orthologues) that comprises a PGECCLP group, an insulin-like growth factor binding protein (IGFBP)-like domain, cysteine-rich domains, an RPD (undefined) group and a transmembrane domain. The protein, e.g. CRIM1, interacts with
CC
Peptides of the transforming growth factor superfamily. A composition comprising an expression construct comprising the nucleic acids of the invention or a mimetic which antagonises or mimics an activity of a CRIM1 polypeptide may be used in a method for modulating the biological activity of a polypeptide of the bone morphogenetic protein (BMP) family. In this way they may be used to prevent or treat an eye disease, especially cataract formation. They may also be used to treat neurodegenerative diseases, renal and kidney disease, bone and tooth abnormalities, wounds and skin damage, e.g. by use of the nucleic acid in gene therapy by using antibodies directed against CRIM1 polypeptides. The present sequence represents human CRIM1 (aka S52).
XX
SQ sequence 1036 AA;
Query Match 99.1%; Score 5901; DB 22; Length 1036;
Best Local Similarity 99.2%; Pred. No. 0;
batches 102B; Conservative 3; Mismatches 5; Indels 0; Gaps 0;
QY 1 MILVAGDRGLAGGGHLVLNSLGLLIPARSPTRAVLCLPCDESKCERPRNRPGSTWQGV 60
Db 1 MYLVAGDRGLAGGGHLVLNSLGLLIPARSPTRAVLCLPCDESKCERPRNRPGSTWQGV 60
QY 61 GGCYCASCQNESSGGFGLXKTCGDLRIVRLPLMSLVEYAGCDEENWDOLL 120
Db 121 GPKPENNLLAGOMLNKCRNTTMCSPFEPSPQMCISLKRTERERPDCKARCE 180
Db 121 GPKPENNLLAGOMLNKCRNTTMCSPFEPSPQMCISLKRTERERPDCKARCE 180
QY 181 VQFSRCPEDPSVLTEQVAPPGSCCLPSPRCVNPAGPGLRKVCPGNNIILYKASKGKPE 240
Db 181 VQFSRCPEDPSVLTEQVAPPGSCCLPSPRCVNPAGPGLRKVCPGNNIILYKASKGKPE 240
QY 241 CCDLYZCKPKFGVNCRTVECPYQTCQMCPPSYEYQVRLTADGCTLPTRDCLSICGF 300
Db 241 CCPLYZCKPKFGVNCRTVECPYQTCQMCPPSYEYQVRLTADGCTLPTRDCLSICGF 300
QY 301 PVCEVESTPRVSYRDPGPKCDVFCYNDTPKACVNNEYTDGMFRMNCRRCQ 360
Db 301 PVCEVESTPRVSYRDPGPKCDVFCYNDTPKACVNNEYTDGMFRMNCRRCQ 360
QY 361 GGAICPAQDGEGENCERYVPPGECPPCVPVCPVDPVPPNPAQGUAANGLLAHDREDD 420
Db 361 GGAICPAQDGEGENCERYVPPGECPPCVPVCPVDPVPPNPAQGUAANGLLAHDREDD 420
QY 421 CTFFQCUNGERHCWAATGCCQCTPNVKVPGECCPPCEEPPLITDPAEGELNCILTRK 480
Db 421 CTFFQCUNGERHCWAATGCCQCTPNVKVPGECCPPCEEPPLITDPAEGELNCILTRK 480
QY 481 DCINGFKRDHGCCRQCOINTCSCSERKQGCTLNGPFGLTDAQNCICECRPRPKCR 540
Db 481 DCINGFKRDHGCCRQCOINTCSCSERKQGCTLNGPFGLTDAQNCICECRPRPKCR 540
QY 541 PIYDKYKCPGSLKLKHKHGIDCKKKPEPLSCKPGLQODSHGCGCLICKCREASASAG 600
Db 541 PIYDKYKCPGSLKLKHKHGIDCKKKPEPLSCKPGLQODSHGCGCLICKCREASASAG 600
QY 601 PRPLSGCTLVDGHAKHKNESWHLGCRBCYCLINGRMALITCPVPAAGNPTHPGCCP 660
Db 601 PRPLSGCTLVDGHAKHKNESWHLGCRBCYCLINGRMALITCPVPAAGNPTHPGCCP 660
QY 661 SCADDFWYKPELSPSICPAQGEGYVEGETWNIDSCTOCTCISGRVLCEDFVPCPLC 720
Db 661 SCADDFWYKPELSPSICPAQGEGYVEGETWNIDSCTOCTCISGRVLCEDFVPCPLC 720
QY 721 ONSRSTDSCPOCTDOPERSRSRNNVSPNICKNDRGDFLAMBSWKPDVCSCIDS 780
Db 721 ONSRSTDSCPOCTDOPERSRSRNNVSPNICKNDRGDFLAMBSWKPDVCSCIDS 780
QY 781 VICSFSESCPSPVSPVSPVLRKGCPYKIDPKKVVCHPSKGKAYDERWLDSCMHC 840
Db 781 VICSFSESCPSPVSPVSPVLRKGCPYKIDPKKVVCHPSKGKAYDERWLDSCMHC 840
Db 781 VICSFSESCPSPVSPVSPVLRKGCPYKIDPKKVVCHPSKGKAYDERWLDSCMHC 840

